IP Library Granted Patent US 10,779,877
Granted Patent B2
US 10,779,877 · App. 16/001,366 · Granted Sep 22, 2020

Power modulated endometrial lining tissue ablation

Inventors: William Lucas Churchill (Bolton, MA); Danielle Gline Allen (Derry, NH)
Assignee: Hologic, Inc.
A61B18/1233A61B2018/0072A61B2018/00267A61B2018/00559A61B2018/00577A61B2018/00642A61B2018/00702A61B2018/00875A61B2018/126A61B2018/1475
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,779,877
App. No.
16/001,366
Granted
Sep 22, 2020
Kind
B2
Abstract

A system is configured to delivering radiofrequency power to the endometrial lining tissue of a uterine cavity, including modulating the delivered power so that a measured impedance of the endometrial lining tissue tracks a target impedance as a function of time, wherein the target tissue impedance is derived from a function that approximates a preferred endometrial lining tissue ablation impedance curve that is determined based upon a measured impedance of the endometrial lining tissue after RF power has been delivered for a predetermined initial time period.

Claims (38)

1. A system for ablating endometrial lining tissue, comprising:

a radiofrequency (RF) applicator configured for being positioned within a uterine cavity;

an RF generator electrically coupled to the RF applicator; and

a controller operatively coupled to the RF generator, wherein the controller is configured to

cause RF power to be delivered from the RF generator to endometrial lining tissue within the uterine cavity via the RF applicator,

after the RF power has been delivered for an initial time period, measure an initial impedance of the endometrial lining tissue using an impedance measurement circuit provided by the RF applicator,

based upon the measured initial impedance, determine a target impedance of the endometrial lining tissue as a function of time for an endometrial lining ablation procedure, and

modulate the RF power delivered to the endometrial lining tissue during the endometrial lining ablation procedure so that an impedance of the endometrial lining tissue tracks the target impedance.

2. The system of claim 1 , wherein the controller is configured to determine the target impedance of the endometrial lining tissue for a duration of the endometrial lining ablation procedure based in part upon by scaling a preexisting endometrial lining tissue ablation impedance curve based upon the measured initial impedance of the endometrial lining tissue.

3. The system of claim 1 , wherein the controller is configured to determine the target impedance of the endometrial lining tissue for a duration of the endometrial lining ablation procedure based in part upon impedance data obtained from prior performed endometrial lining tissue ablation procedures.

4. The system of claim 1 , wherein the RF applicator comprises an electrode carrier including one or more bipolar electrode pairs thereon.

5. The system of claim 1 , wherein the controller is configured to cause the RF power to be delivered at a substantially constant power level during the initial time period.

6. The system of claim 5 , wherein a duration of the initial time period and the substantially constant power level of the delivered RF power during the initial time period are together sufficient such that the measured initial impedance is representative of an electrical conductivity of the endometrial lining tissue.

7. The system of claim 2 , wherein the controller is configured to determine the target impedance of the endometrial lining tissue for the duration of the endometrial lining ablation procedure according to a formula, I t =I max −((I max −I o )*S), where

I t is a target tissue impedance for a given time t during the endometrial lining ablation procedure,

I max is a target maximum impedance of the endometrial lining tissue,

I o is a projected impedance of the endometrial lining tissue for the given time t during the endometrial lining ablation procedure derived from a function approximating the preexisting endometrial lining tissue ablation impedance curve, and

S is a scaling factor equal to (I max −I meas )/(I max −I io ), where I meas is the measured initial impedance of the endometrial lining tissue, t initial , and I io is a projected initial impedance of the endometrial lining tissue derived from the function approximating the preexisting endometrial lining tissue ablation impedance curve.

8. The system of claim 7 , wherein the duration of the endometrial lining ablation procedure is about 120 seconds, I max is about 50 ohms, and the function approximating the preexisting endometrial lining tissue ablation impedance curve is I t =4+(49 (T/120) ), where T is a given time (in seconds) during the endometrial lining ablation procedure.

9. The system of claim 1 , wherein the controller is configured to cause the RF power to be delivered to the endometrial lining tissue until (i) the impedance of the endometrial lining tissue reaches a target maximum tissue impedance, or (ii) a duration of the endometrial lining ablation procedure reaches a target completion time whichever occurs first.

10. The system of claim 1 , wherein the controller is configured to modulate the delivery of the RF power to the endometrial lining tissue by causing one of increasing, decreasing, or maintaining constant a delivered RF current to the endometrial lining tissue at regular power adjustment intervals.

11. The system of claim 10 , wherein, at each power adjustment interval, an amperage of the delivered RF current is not increased or decreased more than a predetermined adjustment limit.

12. The system of claim 11 , wherein the predetermined adjustment limit is about 3%.

13. A system for ablating endometrial lining tissue, comprising:

a radiofrequency (RF) applicator configured to be positioned within a uterine cavity;

an RF generator electrically coupled to the RF applicator; and

a controller operatively coupled to the RF generator, wherein the controller is configured to

cause RF power to be delivered from the RF generator to the endometrial lining tissue within the uterine cavity via the RF applicator,

after the RF power has been delivered for an initial time period, measure an initial impedance of the endometrial lining tissue using an impedance measurement circuit provided by the RF applicator,

modulate the delivery of the RF power to the endometrial lining tissue so that impedance of the endometrial lining tissue tracks a target impedance of the endometrial lining tissue as a function of time for a duration of an endometrial lining ablation procedure derived from impedance data obtained from prior performed endometrial lining tissue ablation procedures, and

cease delivery of the RF power to the endometrial lining tissue when (i) the impedance of the endometrial lining tissue reaches a target maximum tissue impedance, or (ii) the duration of the endometrial lining ablation procedure reaches a target completion time, whichever occurs first.

14. The system of claim 13 , wherein the controller is configured to modulate the delivery of the RF power to the endometrial lining tissue by causing one of increasing, decreasing, or maintaining constant a delivered RF current to the endometrial lining tissue at regular power adjustment intervals, wherein, at each power adjustment interval, an amperage of the delivered RF current is not increased or decreased more than a predetermined adjustment limit.

15. The system of claim 13 , wherein the controller is configured to determine the target impedance of the endometrial lining tissue for the duration of the endometrial lining ablation procedure according to a formula, I t =I max −((I max −I o )*S), where

I t is a target tissue impedance for a given time t during the endometrial lining ablation procedure,

I max is a target maximum impedance of the endometrial lining tissue,

I o is a projected impedance of the endometrial lining tissue for the given time t during the endometrial lining ablation procedure derived from a function approximating a preexisting endometrial lining tissue ablation impedance curve, and

S is a scaling factor equal to (I max −I meas )/(I max −I io ), where I meas is the measured initial impedance of the endometrial lining tissue, and I io is a projected initial impedance of the endometrial lining tissue derived from the function approximating the preexisting endometrial lining tissue ablation impedance curve.

16. The system of claim 15 , wherein the duration of the endometrial lining ablation procedure is about 120 seconds, I max is about 50 ohms, and the function approximating the preexisting endometrial lining tissue ablation impedance curve is I t =4+(49 (T/120) ), where T is a given time (in seconds) during the endometrial lining ablation procedure.

Assignments (5)
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 054089/0804 Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO FOCAL THERAPEUTICS, INC.; GEN-PROBE INCORPORATED; FAXITRON BIOPTICS, LLC; GEN-PROBE PRODESSE, INC.
Reel/Frame 075504/0575 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
SECURITY INTEREST Recorded Oct 15, 2020
From: HOLOGIC, INC.; FAXITRON BIOPTICS, LLC; FOCAL THERAPEUTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 054089/0804 →
SECURITY INTEREST Recorded Oct 19, 2018
From: HOLOGIC, INC.; GEN-PROBE INCORPORATED; CYNOSURE, INC.; FAXITRON BIOPTICS, LLC
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 047272/0347 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2018
From: CHURCHILL, WILLIAM LUCAS; ALLEN, DANIELLE GLINE
To: HOLOGIC, INC.
Reel/Frame 046005/0565 →
Continuity (3)
Continuation 14574070 · Dec 17, 2014
Provisional Application 61920152 · Dec 23, 2013
Related Publication 20180280072A1 · Oct 4, 2018
Cited By (2)
US 12,279,802 US 12,453,595